Abstract
Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Author Contributions
Chezi Ganzel: planned the study, performed the study, wrote the manuscript; Ron Ram: performed the study; Alexander Gural: performed the study; Ofir Wolach: performed the study; Sharon Gino-Moor: performed the study; Vladimir Vainstein: performed the study; Boaz Nachmias: performed the study; Arie Apel: performed the study; Maya Koren-Michowitz: performed the study, contributed to the writing of the manuscript; Oren Pasvolsky: performed the study; Ronit Yerushalmi: performed the study; Ivetta Danylesko: performed the study; Yosef Cohen: performed the study; Galit Peretz: performed the study; Yakir Moshe: performed the study; Miri Zektser: performed the study; Shay Yeganeh: performed the study; Jacob M Rowe: planned the study, contributed to the writing of the manuscript; Yishai Ofran: planned the study, performed the study, contributed to the writing of the manuscript.